| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Chief Strategy Officer | Common Stock | 59,086 | $59,795 | $1.01 | 06 Jan 2026 | Direct |
| AN2 Therapeutics, Inc. | Chief Strategy Officer | Stock Option (right to buy) | 56,000 | 26 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 05 Jan 2026 | 2 | -$6,507 | 4 | Chief Strategy Officer | 07 Jan 2026, 20:15 |
| ANTX | AN2 Therapeutics, Inc. | 04 Nov 2025 | 1 | -$872 | 4 | Chief Strategy Officer | 06 Nov 2025, 18:11 |
| ANTX | AN2 Therapeutics, Inc. | 26 Feb 2025 | 2 | $0 | 4 | Chief Strategy Officer | 28 Feb 2025, 16:19 |
| ANTX | AN2 Therapeutics, Inc. | 03 Jan 2025 | 1 | -$2,721 | 4 | Chief Strategy Officer | 07 Jan 2025, 19:57 |
| ANTX | AN2 Therapeutics, Inc. | 04 Nov 2024 | 2 | $0 | 4 | Chief Strategy Officer | 05 Nov 2024, 16:57 |
| ANTX | AN2 Therapeutics, Inc. | 04 Nov 2024 | 0 | $0 | 3 | Chief Strategy Officer | 05 Nov 2024, 16:49 |